|
Magnetic
Resonance -
Technology
Information
Portal |
Welcome to MRI Technology • |
|
|
 | Info
Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
 | Out-
side |
| | | | |
|
| | | | |
Result : Searchterm 'Resovist' found in 1 term [ ] and 5 definitions [ ]
| | 1 - 5 (of 6) nextResult Pages : [1] [2] | | |  | Searchterm 'Resovist' was also found in the following service: | | | | |
| |  |
| |
|
Resovist® is an organ-specific MRI contrast agent, used for the detection and characterization of especially small focal liver lesions.
Resovist® consists of superparamagnetic iron oxide (SPIO) nanoparticles coated with carboxydextran, which are accumulated by phagocytosis in cells of the reticuloendothelial system (RES) of the liver. The uptake of Resovist® Injection in the reticuloendothelial cells results in a decrease of the signal intensity of normal liver parenchyma on both T2- and T1 weighted images.
Most malignant liver tumors do not contain RES cells and therefore do not uptake the iron particles. The resulting imaging effect is an improved contrast between the tumor (bright) and the surrounding tissue (dark).
Resovist® can be injected as an intravenous bolus, which allows immediate imaging of the liver and reduces the overall examination time. A dynamic imaging strategy after bolus injection supports to characterize lesions.
In comprehensive clinical trials, it demonstrated an excellent safety profile.
In 2001, Resovist® was approved for the European market.
See also Superparamagnetic Iron Oxide.
Resovist® competed with Primovist™, the other liver imaging agent of Bayer Schering Pharma AG. Due to this reason, the production of Resovist® has been abandoned in 2009.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Ferrixan [Ferucarbotran], carboxydextran coated iron oxide nanoparticles
|
| DEVELOPER |
Bayer Schering Pharma AG
|
| CENTRAL MOIETY |
Fe2+ |
| CONTRAST EFFECT |
T2/T1, Predominantly negative enhancement |
| RELAXIVITY |
r1=25.4, r2=151, |
| PHARMACOKINETIC |
RES-directed |
| OSMOLALITY |
333 mosm/kg |
| CONCENTRATION |
0.5 mol Fe/L |
| DOSAGE |
Less than 60 kg = 0.9 ml, greater than 60 kg = 1.4 ml |
| PREPARATION |
Finished product |
| INDICATION |
Liver lesions |
| DISTRIBUTOR |
See below |
| PRESENTATION |
Pre-filled syringes of 0.9 and 1.4 mL |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
|
Distribution Information |
| TERRITORY |
TRADE NAME |
DEVELOPMENT
STAGE |
DISTRIBUTOR |
| USA |
Resovist® |
? |
- |
| Japan |
Resovist® |
approved |
- |
| EU |
Resovist® |
approved |
- |
| Australia |
Resovist® |
Approved |
- |
|
| | | | | | • Share the entry 'Resovist®':    | | | | |  Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | |  |
| |
|
| | | |
• View the DATABASE results for 'Cliavist™' (2).
| | | | |
| | | | | |
| |
|
| | | |
• View the DATABASE results for 'Ferucarbotran' (4).
| | | | |
| | | Searchterm 'Resovist' was also found in the following service: | | | | |
| | |
| |
|
The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology & Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.
|
| |
|
| | | |
• View the DATABASE results for 'Bayer Schering Pharma AG' (22).
| | |
• View the NEWS results for 'Bayer Schering Pharma AG' (25).
| | | | | | Further Reading: | News & More:
|
|
| |
| | | | | |
| |
|
| | | |
• View the DATABASE results for 'SHU 555 C' (2).
| | | | |
| | | | |
| | | 1 - 5 (of 6) nextResult Pages : [1] [2] |
| |
|
| |
 | Look
Ups |
| |
|
| | [last update: 2013-05-20 08:52:15] |
|
|
Random Page
top
